CRPC with Bone Metastases: From the Editor
The Vicious Cycle
Access to Clinical Trials Reverses the Racial Disparity in Lethal Prostate Cancer
Most recent data from SEER reveal that black men in the US have 1.5 times greater chance of developing prostate cancer than white men, and are 2.2 times more likely to die from the disease1.
It Takes A Village: Why It’s Been So Hard to Grow Prostate Cancer Patient-Derived Explants
The State of Bone Health in mCRPC: ERA-223 Results Revealed
My Retirement Plan: 401K, IRA, and…..Prostate Cancer Screening?
From the Desk of the Editor: Non-Metastatic Metastases and Other Confusing Findings from the PROSPER and SPARTAN Trials
From the Desk of the Editor: “Bone Metastases Matter”
Normally, we can see this coming – both in terms of the symptoms progressing through the last year or year and a half of life, as well as the tumor burden. Until recently, it has been hard to quantify these factors.
Bone is the New Primary - Daniel George
In the past, I would smile politely and correct them by saying, “actually what you have is prostate cancer that has spread to your bones.” But, what if they are right? I mean, many of these patients have previously undergone a prostatectomy or radiation therapy, and have no evidence of local disease. Sure, the patient may have an elevated prostate-specific antigen (PSA) level, but does that alone really make this prostate cancer?